Ryusendo Co., Ltd. (HQ: Toshima-ku, Tokyo; CEO: Yoshiaki Shiojima) will officially launch 'Collavant® n2,' a functional ingredient for joint care manufactured by Spain's Bioiberica, in Japan on May 27, 2026. Ryusendo has acquired exclusive distribution rights for the globally branded ingredient in Japan. The company will now begin full-scale promotion of the ingredient for joint health maintenance, active seniors, sports nutrition, and anti-aging sectors. The ingredient will also be featured at a seminar and exhibition booth at 'ifia JAPAN 2026.' ◆ A Next-Generation Joint Care Ingredient Focused on Oral Tolerance: Collavant® n2 is a high-quality, undenatured type II collagen derived from chicken sternum cartilage. Manufactured with a unique European process that preserves the collagen's specific 3D structure, it functions through a mechanism called 'oral tolerance.' A small dose works by modulating the body's excessive immune response to its own type II collagen, thereby supporting joint health. ◆ Clinical Trials Confirm Improved Joint Function and Cartilage Protection: Multiple double-blind clinical studies on healthy subjects experiencing joint discomfort during exercise have shown significant improvements in KOOS scores (a measure of knee injury and osteoarthritis) and a confirmed 18.3% decrease in urinary CTX-II (a biomarker for cartilage degradation) in the Collavant® n2 group, compared to a 20.6% increase in the placebo group. These results demonstrate that Collavant® n2 is a scientifically-backed ingredient for joint care. ◆ Small 40mg Daily Dose Allows for Wide Product Formulation: The recommended daily intake is only 40mg, containing at least 2.4mg of undenatured type II collagen. This low dosage allows for easy application in various product forms, such as hard capsules, tablets, beverages, and gummies. Its neutral flavor and cost-effectiveness also make it suitable for combination with existing formulas (e.g., glucosamine). ◆ A High-Quality Branded Ingred